DOCSLIB.ORG

PN0496-Acotiamide.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Acotiamide hydrochloride hydrate (Acofide®) 盐酸阿考替胺 Z-338 in Zeria; YM-443 in Astellas Tablet, oral, EQ 100 mg acotiamide Acotiamide is a peripheral acetylcholinesterase inhibitor, indicated for the treatment of functional dyspepsia (FD), which was first-in-class drug to treat FD in the world and approved in 2013 by Japan PMDA. It was originally discovered by Zeria, and co-developed with Astellas. The drug is co-marketing in Japan with a single brand name. The human recommended starting dose is 100 mg at a time, and 3 times a day before meals. Worldwide Key Approvals Global Sales ($Million) Key Substance Patent Expiration 2016-May (US5981557A) 2016-May (EP0870765B1) 2013-Mar (JP) Not available 2021-May (JP3181919B2) 2016-May (CN1063442C) Mechanism of Action Acotiamide hydrochloride hydrate is an acetylcholinesterase (AChE) inhibitor and enhanced the acetylcholine (ACh)-induced contraction and motility of the gastric antrum and the gastric body. Target Binding Selectivity In vitro Efficacy In vivo Efficacy Mixed pattern: Ki1= 0.61 µM Effect dose of contraction in gastric sample: Significantly improved the gastrointestinal motility: Ki2= 2.7 µM ACh-induced: at 1 µM In normal and gastric hypomotility dogs: at 10 mg/kg. Inhibition: IC50= 3 µM Electrical-induced: at 0.3 µM In gastric hypomotility rats: at 100 mg/kg. Pharmacokinetics Parameters Rats Dogs Healthy Humans 3 10 3 10 50 mg 100 mg 200 mg 400 mg 800 mg Dose (mg/kg) (i.v.) (p.o.) (i.v.) (p.o.) (p.o.) (p.o.) (p.o.) (p.o.) (p.o.) Tmax (hr) - 0.08 - 0.5 2.75 2.42 2.08 2.25 2.13 Cmax (ng/mL) - 282.1 - 839.4 16.37 30.82 72.4 185.9 318.4 AUCinf (ng·hr/mL) 586.3 271.5 1179.6 1470.5 52.2 171.3 312.8 752.3 1655 T (hr) 0.8 3.7 1.3 3.0 12.9 13.31 10.92 21.69 17.14 In 1/2 Vivo CL or CL/F (L/hr/kg) 4.3 30.7 2.1 6.0 823.1 L/hr 537 L/hr 580.8 L/hr 464.1 L/hr 440.3 L/hr Vd or Vd/F (L/kg) 4.9 165.6 4.2 26.5 NA 1.694 L NA NA NA F (%) - 13.9 - 37.5 NA NA NA NA NA Major Component in Plasma (%) M-1 (70.09) Parent (74.22) Parent Major Metabolite in Plasma (%) M-1 (70.09) M-1 (12.75) M-1, M2 (inactive) Excretion by Urine/Feces (%) 7/91 7/93 5/87 -6 Permeability Papp (A→B) = 0.8 ~1.3 ×10 cm/s at concentrations of 1 – 500 µM in Caco-2 cells. In PPB (%Bound) 75.16-77.52 53.39-61.02 84.21-85.95 Vitro Metabolic stability in LM (%Remaining) 90.3 100 42.3 Drug-Drug Interaction CYP Enzymes Other Enzymes Transporters Substrate CYP2C8 UGT1A8, UGT1A9 P-gp Inhibitor Not NA P-gp (low) Inducer Not NA NA Non-clinical Toxicology Single Dose Rats: 2000 mg/kg Safety • Nothing special observed in a bunch of safety pharmacology studies Dogs: 2000 mg/kg Pharmacology Toxicity (MTD) Genotoxicity • No genetic toxicity was found. • Fertility: NOAEL: 1000 mg/kg/day in rats. Rats: 300 mg/kg/day • Embryo-fetal developemt: maternal NOAEL: 300 & 100 mg/kg/day (13 29 & 12×MRHD Repeated Dose Reproductive & 2.2×MRHD); developmental NOAEL: 1000 & 300 mg/kg/day (19 & Dogs: 30&100mg/kg/day Toxicity Toxicity 24×MRHD). (rats & rabbits) 6 & 10×MRHD (NOAEL) • Postnatal development: NOAEL: 1000 mg/kg/day for F0 and F1 in rats. (Male & Female) • Transferred through placenta and excreted through milk. • Endometrial adenocarcinoma incidence increased was found in 2-year Carcinogenicity rat tests, but not found in rasH2 transgenic accelerating tests. Acotiamide hydrochloride hydrate 1 Acotiamide hydrochloride hydrate (Acofide®) 盐酸阿考替胺 Research code: Z-338 in Zeria; YM-443 in Astellas §1 General Information Acotiamide is a peripheral acetylcholinesterase (AChE) in- hibitor, is the first-in-class drug to treat FD in the world, which was approved in 2013 by PMDA of Japan. It was originally discovered by Zeria, and co-developed with Astellas. The drug is co-marketing in Japan with a sin- gle brand name. Acotiamide prevents the hydrolysis of acetylcholine by in- hibiting peripheral acetylcholinesterase, and produces the . improvement of impaired gastric motility and delayed gas- Molecular formula: C21H30N4O5S HCl 3H2O tric emptying, and consequently the symptoms of FD. Molecular weight: 541.06 Acotiamide is indicated for the treatment of postprandial CAS No.: 185106-16-5 (acotiamide) fullness, upper abdominal bloating, and early satiation due 773092-05-0 (acotiamide hydrochloride trihy- to functional dyspepsia. drate) Available as orally tablets, containing 100 mg of acoti- amide hydrochloride hydrate and the recommended start- Parameters of Lipinski’s “Rule of 5” ing dose is 100 mg at a time, and 3 times a day before meals. a b b b MW HD HA FRB PSA CLogP --Key Approvals around the World-- 450.55 3 9 10 141Å2 4.873±0.434 a: molecular weight of acotiamide; b: Calculated by ACD/Labs software V11.02 Country Japan (PMDA) (or Area) --Drug Product-- First Ap- 2013/3/25 proval Date Dosage route: Oral. NDA NO. 22500AMX00868000 Strengths: 100 mg (EQ to Acotiamide) Dosage forms: Tablet, film coated Brand Name Acofide Inactive ingredients: Indication Functional dyspepsia Lactose hydrate, Crystalline cellulose, Low-substituted Authorization hydroxypropyl cellulose, Hydroxypropyl cellulose, Zeria/Astalles Holder Light anhydrous silicic acid, Magnesium stearate, *: Till May. 2015, it has not been approved by FDA (US), EMA (EU) and CFDA Hypromellose, Carnauba wax and Titanium oxide. (China). Recommended dose: --Worldwide Sales-- In general, for adults, take 1 tablet at a time, 3 times a day before meals. * Sourced from the Japan PMDA drug label information *: The sale data of Acofide® was not available. --Active Ingredient-- The Pharmaceutical Index – Worldwide 2013 NCEs 2 --Key Patents-- Patent 1 Title Aminothiazole derivatives, drug containing the same and intermediate in the production of the compounds International International Patent Type Applicants WO Patent NO. Priority Date Application NO. Filling Date Product(Substance) Zeria Pharm Co Ltd WO9636619A1 WOJP96001297 1995/5/18 1996/5/16 Drug Approval National Patent NO. Application Date Granted Date Patent Extension Patent Expiration Date US5981557A 1996/5/16 1999/11/9 NA / 2016/5/16 EP0870765B1 1996/5/16 2003/11/19 NA / 2016/5/16 JP3181919B2 1996/5/16 2001/7/3 2013/3/25 5 years 2021/5/16 CN1063442C 1996/5/16 2001/3/21 NA / 2016/5/16 Patent 2 Title Method for treatment of climacteric disorders in woman during or after the menopause International International Patent Type Applicants WO Patent NO. Priority Date Application NO. Filling Date Uses Hormos Medical Co. WO0207718A1 PCT/FI01/00414 2000/7/21 2001/5/2 Drug Approval National Patent NO. Application Date Granted Date Patent Extension Patent Expiration Date US6245819B1 2000/7/21 2001/6/12 2013/2/26 0 day 2020/7/21 US6984665B2 2001/5/2 2001/6/12 2013/2/26 354 days 2022/4/21 EP1305014B1 2001/5/2 2006/1/10 NA / 2021/5/2 JP5575351B2 2001/5/2 2005/7/27 2013/3/25 NA 2021/5/2 JP5629746B2 2001/5/2 2014/8/20 2013/3/25 NA 2021/5/2 CN1287775C 2001/5/2 2014/11/26 NA / 2021/5/2 Acotiamide hydrochloride hydrate 3 §2 Chemistry Route 1: Original Discovery Route[1] Journal Citation/ Reference Title Comments Patent NO. Aminothiazole derivatives, drug containing the same and intermedi- WO9636619A1 1 Key Ref. ate in the production of the compounds US5981557A Route 2[2, 3]: Journal Citation/ Reference Title Comments Patent NO. Preparation of 2-bromo-4,5-dialkoxybenzoic WO2012077673A1 2 Key Ref. acid in high efficiency at low cost US20130253222A1 Method for producing aminothiazole derivative and production inter- WO2006022252A1 3 mediate US8772528B2 The Pharmaceutical Index – Worldwide 2013 NCEs 4 Route 3[4, 5]: Journal Citation/ Reference Title Comments Patent NO. WO9858918A1 4 Process for producing 2-hydroxybenzamide derivatives Key Ref. US6197970B1 5 Synthetic method of acotiamide hydrochloride hydrate CN103709191A Route 4[6]: Journal Citation/ Reference Title Comments Patent NO. 6 One-pot method for preparing acotiamide hydrochloride CN104045606A Key Ref. Acotiamide hydrochloride hydrate 5 Route 5[7]: Journal Citation/ Reference Title Comments Patent NO. 7 Method for preparing acotiamide hydrochloride CN103387552A Key Ref. The Pharmaceutical Index – Worldwide 2013 NCEs 6 §3 Pharmacology Mechanism of Action Acotiamide hydrochloride hydrate is an acetylcholinesterase (AChE) inhib- itor and enhanced the acetylcholine (ACh)-induced contraction and motility of the gastric antrum and the gastric body. Acotiamide inhibited AChE with mixed pattern (Ki1=0.61±0.03 µM , Ki2=2.7±0.2 µM , and IC50=3 µM) and suppressed the degradation of acetyl- choline (ACh) released from cholinergic nerve terminals[8]. The AChE inhibitory effect of Acotiamide almost disappeared by dialysis, [8] it was shown to be reversible . Acotiamide did not show a high affinity to the muscarinic M1, M2, M3 re- ceptors, dopamine D2S receptors and serotonin 5-HT4 receptors involved in the regulation of gastrointestinal motility[8]. In Vitro Efficacy Acotiamide improved ACh-induced contraction in gastric sample in vitro at 1 µM[8]. Acotiamide improved electrical-induced contraction in gastric sample in vitro at 0.3 µM[8]. In Vivo Efficacy [8] Acotiamide significantly improved the gastrointestinal motility : In normal and clonidine-induced gastric antrum hypomotility dogs: at 10 mg/kg dose. In normal rats: at 30 mg/kg dose. In clonidine-induced gastric antrum hypomotility rats: at 100 mg/kg. [8] Significantly improved clonidine-induced delayed gastric emptying in rats: at 100 mg/kg, s.c.
Recommended publications
  • Real World Efficacy and Tolerability of Acotiamide, in Relieving Meal

    Real World Efficacy and Tolerability of Acotiamide, in Relieving Meal

    testinal & in D o i tr g s e Journal of Gastrointestinal & a s t G i v f e o Narayanan et al., J Gastrointest Dig Syst 2018, 8:1 S l y a s n r ISSN: 2161-069Xt Digestive System DOI: 10.4172/2161-069X.1000553 e u m o J Research Article Open Access Real World Efficacy and Tolerability of Acotiamide, in Relieving Meal- related Symptoms of Functional Dyspepsia Varsha Narayanan*, Amit Bhargava and Shailesh Pallewar 1Department of Medical Services and Research, Lupin Ltd., India *Corresponding author: Narayanan V, Department of Medical Services and Research, Lupin Ltd., Mumbai, India, Tel: +912266402222; E-mail: [email protected] Received date: February 09, 2018; Accepted date: February 21, 2018; Published date: February 27, 2018 Copyright: © 2018 Narayanan V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Background: Functional Dyspepsia (FD) is a highly prevalent clinical condition that imposes negative economic burden on health-care system as well as greatly impairs quality of life. Treatment of non-specific and bothersome meal-related FD symptoms like post-prandial fullness, upper abdominal bloating and early satiety, is a therapeutic challenge for the clinicians as poorly-defined and ill-understood pathogenesis has hampered efforts to develop effective treatments. Acotiamide is first-in-class drug that exerts its gastro-kinetic effect by enhancing acetylcholine release. Though evidence of its efficacy and tolerance are available through randomized clinical trials, real world data from its regular in-clinic use is lacking.
  • Pharmacological Agents Currently in Clinical Trials for Disorders in Neurogastroenterology

    Pharmacological Agents Currently in Clinical Trials for Disorders in Neurogastroenterology

    Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri J Clin Invest. 2013;123(10):4111-4120. https://doi.org/10.1172/JCI70837. Clinical Review Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain. Find the latest version: https://jci.me/70837/pdf Review Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA. Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in under- standing the mechanisms of these disorders, through basic and translational research, and in targeting the recep- tors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastropa- resis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • Gastroparesis: 2014

    Gastroparesis: 2014

    GASTROINTESTINAL MOTILITY AND FUNCTIONAL BOWEL DISORDERS, SERIES #1 Richard W. McCallum, MD, FACP, FRACP (Aust), FACG Status of Pharmacologic Management of Gastroparesis: 2014 Richard W. McCallum Joseph Sunny, Jr. Gastroparesis is characterized by delayed gastric emptying without mechanical obstruction of the gastric outlet or small intestine. The main etiologies are diabetes, idiopathic and post- gastric and esophageal surgical settings. The management of gastroparesis is challenging due to a limited number of medications and patients often have symptoms, which are refractory to available medications. This article reviews current treatment options for gastroparesis including adverse events and limitations as well as future directions in pharmacologic research. INTRODUCTION astroparesis is a syndrome characterized by documented gastroparesis are increasing.2 Physicians delayed emptying of gastric contents without have both medical and surgical approaches for these Gmechanical obstruction of the stomach, pylorus or patients (See Figure 1). Medical therapy includes both small bowel. Patients can present with nausea, vomiting, prokinetics and antiemetics (See Table 1 and Table 2). postprandial fullness, early satiety, pressure, fullness The gastroparesis population will grow as diabetes and abdominal distension. In addition, abdominal pain increases and new therapies will be required. What located in the epigastrium, and distinguished from the do we know about the size of the gastroparetic term discomfort, is increasingly being recognized population? According to a study from the Mayo Clinic as an important symptom. The main etiologies of group surveying Olmsted County in Minnesota, the gastroparesis are diabetes, idiopathic, and post gastric risk of gastroparesis in Type 1 diabetes mellitus was and esophageal surgeries.1 Hospitalizations from significantly greater than for Type 2.
  • Functional Dyspepsia: a Review of the Symptoms, Evaluation, and Treatment Options

    Functional Dyspepsia: a Review of the Symptoms, Evaluation, and Treatment Options

    Functional Dyspepsia: A Review of the Symptoms, Evaluation, and Treatment Options Kimberly N. Harer, MD, ScM, and William L. Hasler, MD Dr Harer is a clinical lecturer and Dr Abstract: The community prevalence of dyspepsia ranges from Hasler is a professor in the Division of 20% to 40%, and dyspepsia accounts for 3% to 5% of primary care Gastroenterology in the University of visits. Dyspepsia symptoms include epigastric pain, epigastric burn- Michigan Health System in Ann Arbor, ing, postprandial fullness, early satiety, epigastric bloating, nausea, Michigan. and belching. Functional dyspepsia is diagnosed when an organic etiology for the symptoms is not identified. Diagnostic symptom- Address correspondence to: based criteria are defined by Rome IV. Functional dyspepsia is Dr William L. Hasler further subclassified into postprandial distress syndrome and University of Michigan Health System epigastric pain syndrome based on the predominance of post- 3912 Taubman Center, SPC 5362 prandial bloating and fullness vs epigastric pain. Evaluation of Ann Arbor, MI 48109 Tel: 734-936-4780 functional dyspepsia is driven by patient age and the presence of Fax: 734-936-7392 red-flag symptoms, such as patients over age 60 years or those with E-mail: [email protected] anemia undergoing evaluation with esophagogastroduodenoscopy. Helicobacter pylori infection should be excluded in all patients. Treatment options include proton pump inhibitors, neuromodu- lators, and prokinetics; however, the evidence supporting these therapies is weak, and the response rate is less than robust. he diagnosis and treatment of functional dyspepsia is often clinically challenging due to factors such as the heterogene- ity of upper gastrointestinal symptoms and the generalized Tpoor response to currently available treatment options.
  • Prokinetics for the Treatment of Functional Dyspepsia: Bayesian

    Prokinetics for the Treatment of Functional Dyspepsia: Bayesian

    Yang et al. BMC Gastroenterology (2017) 17:83 DOI 10.1186/s12876-017-0639-0 RESEARCH ARTICLE Open Access Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis Young Joo Yang, Chang Seok Bang* , Gwang Ho Baik, Tae Young Park, Suk Pyo Shin, Ki Tae Suk and Dong Joon Kim Abstract Background: Controversies persist regarding the effect of prokinetics for the treatment of functional dyspepsia (FD). This study aimed to assess the comparative efficacy of prokinetic agents for the treatment of FD. Methods: Randomized controlled trials (RCTs) of prokinetics for the treatment of FD were identified from core databases. Symptom response rates were extracted and analyzed using odds ratios (ORs). A Bayesian network meta- analysis was performed using the Markov chain Monte Carlo method in WinBUGS and NetMetaXL. Results: In total, 25 RCTs, which included 4473 patients with FD who were treated with 6 different prokinetics or placebo, were identified and analyzed. Metoclopramide showed the best surface under the cumulative ranking curve (SUCRA) probability (92.5%), followed by trimebutine (74.5%) and mosapride (63.3%). However, the therapeutic efficacy of metoclopramide was not significantly different from that of trimebutine (OR:1.32, 95% credible interval: 0.27–6.06), mosapride (OR: 1.99, 95% credible interval: 0.87–4.72), or domperidone (OR: 2.04, 95% credible interval: 0.92–4.60). Metoclopramide showed better efficacy than itopride (OR: 2.79, 95% credible interval: 1. 29–6.21) and acotiamide (OR: 3.07, 95% credible interval: 1.43–6.75). Domperidone (SUCRA probability 62.9%) showed better efficacy than itopride (OR: 1.37, 95% credible interval: 1.07–1.77) and acotiamide (OR: 1.51, 95% credible interval: 1.04–2.18).
  • An Updated Review on Banned and Approved Fixed Dose Combination Drugs in India, 2016

    An Updated Review on Banned and Approved Fixed Dose Combination Drugs in India, 2016

    ISSN 2395-3411 Available online at www.ijpacr.com 8 ___________________________________________________________Review Article An Updated Review on Banned and Approved Fixed Dose Combination Drugs in India, 2016 Dhanisiri Gnapika* and Maddi Ramaiah Department of Pharmacognosy, Hindu College of Pharmacy, Guntur – 522002, Andhra Pradesh, India. _______________________________________________________________________ ABSTRACT The Indian pharma industry ranks 14th in terms of value and 3rd in terms of volume in the world. There are 74 US FDA-approved manufacturing facilities in India. A dose is the quantity to be administered at one time, or the total quantity administered during a specified period. A combination of two or more actives in a fixed ratio of doses is known as fixed dose combination. The development of fixed-dose combinations (FDCs) is becoming increasingly important from a public health perspective. However, because of un-avoided dangerous adverse effects, Central Government of India banned about 344 FDCs on March 10th 2016 as per recommendations of six-member committee headed by CK Kokate. Banned drugs are still available in India due to lack of awareness and law enforcement. The present article provides a complete list of approved and banned FDCs in 2016. The pharmacist should play an active role in patient education of such banned and approved drugs regularly and then play an key role in maintain healthy India. Keywords: Dose, FDC, Banned drugs, Approved drugs. INTRODUCTION Department of Pharmaceuticals, Ministry of A dose is the quantity to be administered at Chemicals and Fertilizers3. one time, or the total quantity administered In terms of the global market, India currently during a specified period.
  • Tender Ref. No.: BPPI/DRUG/RC-156/2020 Dated: 17/07/2020

    Tender Ref. No.: BPPI/DRUG/RC-156/2020 Dated: 17/07/2020

    Tender Ref. No.: BPPI/DRUG/RC-156/2020 Dated: 17/07/2020 BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (Set up under the Department of Pharmaceuticals, Govt. of India) 8th Floor, Videocon Tower, Block E1 Jhandewalan Extension, New Delhi-110055 Telephone: 011- 011-49431800/49431812/49431829/49431854; Website: janaushadhi.gov.in e- TENDER FOR SUPPLY OF DRUGS TO BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI) FOR TWO YEARS RATE CONTRACT LAST DATE FOR ONLINE SUBMISSION OF TENDER: 10/08/2020 BPPI/DRUG/RC-156/2020 1 BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI) (SET UP UNDER THE DEPARTMENT OF PHARMACEUTICALS, GOVERNMENT OF INDIA) Regd. Office: Core No. 6, First Floor, SCOPE Complex, Lodi Road, New Delhi-110003 Working Office: 8th Floor, Videocon Tower, Block E1, Jhandewalan Extension, New Delhi-110055 Telephone: 011- 49431800/49431812/49431829/49431854; Website: janaushadhi.gov.in e-TENDER FOR TWO YEARS RATE CONTRACT FOR SUPPLY OF DRUGS TO BUREAU OF PHARMA PSU OF INDIA Tender Reference BPPI/DRUG/RC-156/2020 Dt. 17/07/2020 Tender Website https://eprocure.gov.in Date of availability of tender documents On 17/07/2020 (Friday) on website Doubts and queries regarding Tender document should be sent by e-mail to e-mail id “[email protected] On 23/07/2020 upto 17.00 Hours [email protected], [email protected]” by the likely bidders latest by Time and date and place pre-bid meeting On 24/07/2020 (Friday) at 11:00 AM Bureau of Pharma PSUs of India, 8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi- 110055 Last date and time for submission of On 10/08/2020 up to 17.00 Hours.
  • Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions

    Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions

    1521-0081/68/1/168–241$25.00 http://dx.doi.org/10.1124/pr.115.011411 PHARMACOLOGICAL REVIEWS Pharmacol Rev 68:168–241, January 2016 Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: MARKKU KOULU Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions Janne T. Backman, Anne M. Filppula, Mikko Niemi, and Pertti J. Neuvonen Department of Clinical Pharmacology, University of Helsinki (J.T.B., A.M.F., M.N., P.J.N.), and Helsinki University Hospital, Helsinki, Finland (J.T.B., M.N., P.J.N.) Abstract ...................................................................................169 I. Introduction . ..............................................................................169 II. Basic Characteristics of Cytochrome P450 2C8 . ..........................................170 A. Genomic Organization and Transcriptional Regulation . ...............................170 B. Protein Structure ......................................................................171 C. Expression .............................................................................172 III. Substrates of Cytochrome P450 2C8. ......................................................173 A. Drugs..................................................................................173 1. Anticancer Agents...................................................................173 Downloaded from 2. Antidiabetic Agents. ................................................................183 3. Antimalarial Agents.................................................................183
  • Acetylcholinesterase

    Acetylcholinesterase

    AChE Acetylcholinesterase Acetylcholinesterase (AChE or acetylhydrolase) is a hydrolase that hydrolyzes the neurotransmitter acetylcholine. AChE is found at mainly neuromuscular junctions and cholinergic brain synapses, where its activity serves to terminate synaptic transmission. It belongs tocarboxylesterase family of enzymes. It is the primary target of inhibition by organophosphorus compounds such as nerve agents and pesticides. AChE has a very high catalytic activity - each molecule of AChE degrades about 25000 molecules ofacetylcholine (ACh) per second, approaching the limit allowed by diffusion of the substrate. ACh is released from the nerve into the synaptic cleft and binds to ACh receptors on the post-synaptic membrane, relaying the signal from the nerve. AChE, also located on the post-synaptic membrane, terminates the signal transmission by hydrolyzing ACh. The liberated choline is taken up again by the pre-synaptic nerve and ACh is synthetized by combining with acetyl-CoA through the action of choline acetyltransferase. www.MedChemExpress.com 1 AChE Inhibitors & Activators (+)-Phenserine (-)-Corynoxidine Cat. No.: HY-16009 Cat. No.: HY-N7010 (+)-Phenserine is a novel selective cholinesterase (-)-Corynoxidine is an acetylcholinesterase noncompetitive inhibitor with an IC50 of 45.3 μM. inhibitor with an IC50 value of 89.0 μM, isolated from the aerial parts of Corydalis speciosa. (-)-Corynoxidine exhibits antibacterial activities against Staphylococcus aureus and methicillin-resistant S. Purity: 98.09% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg Size: 1 mg, 5 mg (-)-Huperzine A (R)-Rivastigmine D6 tartrate (Huperzine A) Cat. No.: HY-17387 Cat. No.: HY-11017AS (-)-Huperzine A (Huperzine A) is an alkaloid (R)-Rivastigmine D6 tartrate is the deuterium isolated from a Chinese club moss, with labeled (R)-Rivastigmine, which is an neuroprotective activity.
  • Blefjell Sykehus HF Oslo Universitetssykehus HF

    Blefjell Sykehus HF Oslo Universitetssykehus HF

    Blefjell sykehus HF Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group O. Dahl;O. Fluge;E. Carlsen;J. N. Wiig;H. E. Myrvold;B. Vonen;N. Podhorny;O. Bjerkeset;T. J. Eide;T. B. Halvorsen;K. M. Tveit Acta Oncol 2009 PMID:19242829 Associations between ward atmosphere, patient satisfaction and outcome K. N. Jorgensen;V. Romma;T. Rundmo J Psychiatr Ment Health Nurs 2009 PMID:19281541 Variability in aggregometry response before and after initiation of clopidogrel therapy O. Meen;F. Brosstad;S. Bjornsen;T. M. Pedersen;G. Erikssen Scand J Clin Lab Invest 2009 PMID:19484660 [Can psychiatric acute teams reduce acute admissions to psychiatric wards?] O. B. Kolbjornsrud;F. Larsen;G. Elbert;T. Ruud Tidsskr Nor Laegeforen 2009 PMID:19823203 Oslo universitetssykehus HF A two-year prospective controlled study of bone mass and bone turnover in children with early juvenile idiopathic arthritis G. Lien;A. M. Selvaag;B. Flato;M. Haugen;O. Vinje;D. Sorskaar;K. Dale;T. Egeland;O. Forre Arthritis Rheum 2005 PMID:15751052 Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation B. Fellstrom;A. G. Jardine;I. Soveri;E. Cole;H. H. Neumayer;B. Maes;C. Gimpelewicz;H. Holdaas Am J Transplant 2005 PMID:15996249 Cytokines, bone turnover markers and weight change in candidates for lung transplantation L. Forli;O. J. Mellbye;J. Halse;O. Bjortuft;M. Vatn;J. Boe Pulm Pharmacol Ther 2008 PMID:17419084 The "Romsas in Motion" community intervention: mediating effects of psychosocial factors on forward transition in the stages of change in physical activity C.
  • WO 2007/061529 Al

    WO 2007/061529 Al

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 31 May 2007 (31.05.2007) PCT WO 2007/061529 Al (51) International Patent Classification: GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, A61K 9/14 (2006.01) KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV,LY,MA, MD, MG, MK, MN, MW, MX, MY, MZ, (21) International Application Number: NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, PCT/US2006/040197 SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (22) International Filing Date: 13 October 2006 (13.10.2006) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (26) Publication Language: English ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV,MC, NL, PL, PT, (30) Priority Data: RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, 11/282,507 18 November 2005 (18.1 1.2005) US GN, GQ, GW, ML, MR, NE, SN, TD, TG). (71) Applicant (for all designated States except US): SCI- Declarations under Rule 4.17: DOSE PHARMA INC.